Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N -[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1 H -imidazole-2-carboxamide (JNJ-28312141)

Journal of Medicinal Chemistry

Volumn 54, Issue 22, 2011, Pages 7860-7883

  Illig, Carl R ^a   Manthey, Carl L ^a   Wall, Mark J ^a   Meegalla, Sanath K ^a   Chen, Jinsheng ^a   Wilson, Kenneth J ^a   Ballentine, Shelley K ^a   Desjarlais, Renee L ^a   Schubert, Carsten ^a   Crysler, Carl S ^a   Chen, Yanmin ^a   Molloy, Christopher J ^a   Chaikin, Margery A ^a   Donatelli, Robert R ^a   Yurkow, Edward ^a   Zhou, Zhao ^a   Player, Mark R ^a   Tomczuk, Bruce E ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 AMINO 3 BROMO PHENYL)PIPERIDINE 1 CARBOXYLIC ACID TERT BUTYL ESTER; 4 (4 AMINO 3 CYCLOHEX 1 ENYL PHENYL)PIPERIDINE 1 CARBOXYLIC ACID TERT BUTYL ESTER; 4 (4 AMINO PHENYL) 3,6 DIHYDRO 2H PYRIDINE 1 CARBOXYLIC ACID TERT BUTYL ESTER; 4 (4 AMINO PHENYL)PIPERIDINE 1 CARBOXYLIC ACID TERT BUTYL ESTER; 4 [4 [(4 CYANO 1H IMIDAZOLE 2 CARBONYL)AMINO] 3 CYCLOHEX 1 ENYL PHENYL]PIPERIDINE 1 CARBOXYLIC ACID AMIDE; 4 [4 [(4 CYANO 1H IMIDAZOLE 2 CARBONYL)AMINO] 3 CYCLOHEX 1 ENYL PHENYL]PIPERIDINE 1 CARBOXYLIC ACID(2 HYDROXYETHYL)AMIDE; 4 CYANO 1 (2 TRIMETHYLSILANYL ETHOXYMETHYL) 1H IMIDAZOLE 2 CARBOXYLIC ACID(2 CYCLOHEX 1 ENYL 4 PIPERIDIN 4 YL PHENYL)AMIDE TRIFLUOROACETIC ACID SALT; 4 CYANO 1H IMIDAZOLE 2 CARBOXYLIC ACID(2 CYCLOHEX 1 ENYL 4 PIPERIDIN 4 YL PHENYL)AMIDE TRIFLUOROACETIC ACID SALT; 4 CYANO 1H IMIDAZOLE 2 CARBOXYLIC ACID[2 CYCLOHEX 1 ENYL 4 [1 (2 DIMETHYLAMINO ACETYL)PIPERIDIN 4 YL]PHENYL]AMIDE; 4 CYANO 1H IMIDAZOLE 2 CARBOXYLIC ACID[2 CYCLOHEX 1 ENYL 4 [1 (2 HYDROXY ETHYL)PIPERIDIN 4 YL]PHENYL]AMIDE TRIFLUOROACETIC ACID SALT; 4 CYANO 1H IMIDAZOLE 2 CARBOXYLIC ACID[2 CYCLOHEX 1 ENYL 4 [1 (2 METHANESULFONYL ETHYL)PIPERIDIN 4 YL]PHENYL]AMIDE; 4 CYANO 1H IMIDAZOLE 2 CARBOXYLIC ACID[2 CYCLOHEX 1 ENYL 4 [1 (2 MORPHOLIN 4 YL ACETYL)PIPERIDIN 4 YL]PHENYL]AMIDE; 4 CYANO 1H IMIDAZOLE 2 CARBOXYLIC ACID[2 CYCLOHEX 1 ENYL 4 [1 (2 MORPHOLIN 4 YL ETHYL)PIPERIDIN 4 YL]PHENYL]AMIDE TRIFLUOROACETIC ACID SALT; 4 CYANO 1H IMIDAZOLE 2 CARBOXYLIC ACID[2 CYCLOHEX 1 ENYL 4 [1 (2 PYRIDIN 2 YL ACETYL)PIPERIDIN 4 YL]PHENYL]AMIDE TRIFLUOROACETIC ACID SALT; 4 CYANO 1H IMIDAZOLE 2 CARBOXYLIC ACID[2 CYCLOHEX 1 ENYL 4 [1 (PYRIDINE 3 CARBONYL)PIPERIDIN 4 YL]PHENYL]AMIDE; 4 CYANO 1H IMIDAZOLE 2 CARBOXYLIC ACID[2 CYCLOHEX 1 ENYL 4 [1 [2 (2 HYDROXY ETHYLAMINO)ACETYL]PIPERIDIN 4 YL]PHENYL]AMIDE TRIFLUOROACETIC ACID SALT; 4 CYANO 1H IMIDAZOLE 2 CARBOXYLIC ACID[4 (1 ACETYL PIPERIDIN 4 YL) 2 CYCLOHEX 1 ENYL PHENYL]AMIDE; 4 CYANO N [2 (1 CYCLOHEXEN 1 YL) 4 [1 [(DIMETHYLAMINO)ACETYL] 4 PIPERIDINYL]PHENYL] 1H IMIDAZOLE 2 CARBOXAMIDE; 5 CYANO 1H IMIDAZOLE 2 CARBOXYLIC ACID[4 [1 (2 AMINO 2 METHYL PROPIONYL)PIPERIDIN 4 YL] 2 CYCLOHEX 1 ENYL PHENYL]AMIDE TRIFLUOROACETIC ACID SALT; [4 [4 [(4 CYANO 1H IMIDAZOLE 2 CARBONYL)AMINO] 3 CYCLOHEX 1 ENYL PHENYL]PIPERIDIN 1 YL]ACETIC ACID TRIFLUOROACETIC ACID SALT; [4 [[4 CYANO 1 (2 TRIMETHYLSILANYL ETHOXYMETHYL) 1H IMIDAZOLE 2 CARBONYL]AMINO] 3 CYCLOHEX 1 ENYL PHENYL]PIPERIDINE 1 CARBOXYLIC ACID TERT BUTYL ESTER; ANTIINFLAMMATORY AGENT; COLONY STIMULATING FACTOR 1; JNJ 28312141; UNCLASSIFIED DRUG;

ALKYLATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; ARTHRITIS; ARTICLE; BACTERIAL CELL WALL; CHEMICAL REACTION; COLLAGEN INDUCED ARTHRITIS; COMPETITIVE INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; DRUG POTENCY; DRUG SCREENING; DRUG SOLUBILITY; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IC 50; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PHARMACODYNAMICS; RAT; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, EXPERIMENTAL; CELL LINE, TUMOR; CELL MEMBRANE PERMEABILITY; CELL PROLIFERATION; CRYSTALLOGRAPHY, X-RAY; FEMALE; HUMANS; IMIDAZOLES; MACROPHAGES; MALE; MICE; MICROSOMES, LIVER; MODELS, MOLECULAR; PIPERIDINES; PROTEIN CONFORMATION; RATS; RATS, INBRED LEW; RECEPTOR, MACROPHAGE COLONY-STIMULATING FACTOR; SOLUBILITY; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 81555228207     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm200900q     Document Type: Article

References (76)

1. Lundkvist, J.; Kastang, F.; Kobelt, G. The burden of rheumatoid arthritis and access to treatment: Health burden and costs Eur. J. Health Econ. 2008, 8 (Suppl. 2) S49-S60
2. Maggon, K. Global arthritis market review 2008 (World top ten RA drugs); http://knol.google.com/k/global-arthritis-market-review-2008-world-top-ten-ra- drugs# (accessed January 3, 2011).
3. Lipsky, P. E.; van der Heijde, D. M. F. M.; Clair, E. W., St.; Furst, D. E.; Breedveld, F. C.; Kalden, J. R.; Smolen, J. S.; Weisman, M.; Emery, P.; Feldmann, M.; Harriman, G. R.; Maini, R. N. Infliximab and methotrexate in the treatment of rheumatoid arthritis N. Engl. J. Med. 2000, 343, 1594-1602 (Pubitemid 32162982)
4. Esposito, E.; Cuzzocrea, S. TNF-alpha as a therapeutic target in inflammatory diseases, ischemia-reperfusion injury and trauma Curr. Med. Chem. 2009, 16, 3152-3167
5. Ranganathan, P. An update on pharmacogenomics in rheumatoid arthritis with a focus on TNF-blocking agents Curr. Opin. Mol. Ther. 2008, 10, 562-567
6. Fujiwara, N.; Kobayashi, K. Macrophages in inflammation Curr. Drug Target Inflamm. Allergy 2005, 4, 281-286 (Pubitemid 40873112)
7. Tak, P. P.; Smeets, T. J.; Daha, M. R.; Kluin, P. M.; Meijers, K. A.; Brand, R.; Meinders, A. E.; Breedveld, F. C. Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to disease activity Arthritis Rheum. 1997, 40, 217-25 (Pubitemid 27114085)
8. Haringman, J. J.; Gerlag, D. M.; Zwinderman, A. H.; Smeets, T. J. M.; Kraan, M. C.; Baeten, D.; McInnes, I. B.; Bresnihan, B.; Tak, P. P. Synovial tissue macrophages: A sensitive biomarker for response to treatment in patients with rheumatoid arthritis Ann. Rheum. Dis. 2005, 64, 834-838 (Pubitemid 40733904)
9. Pixley, F. J.; Stanley, E. R. CSF-1 regulation of the wandering macrophage: complexity in action Trends Cell Biol. 2004, 14, 628-638 (Pubitemid 39440612)
10. Hamilton, J. A. Colony-stimulating factors in inflammation and autoimmunity Nature Rev. Immunol. 2008, 8, 533-544 (Pubitemid 351913679)
11. Hamilton, J. A.; Filonzi, E. L.; Ianches, G. Regulation of macrophage colony-stimulating factor (CSF-1) production in cultured human synovial fibroblasts Growth Factors 1993, 9, 157-65 (Pubitemid 23258952)
12. Campbell, I. K.; Ianches, G.; Hamilton, J. A. Production of macrophage colony-stimulating factor (CSF-1) by human articular cartilage and chondrocytes. Modulation by interleukin-1 and tumor necrosis factor alpha Biochim. Biophys. Acta 1993, 1182, 57-63 (Pubitemid 23233674)
13. Nakano, K.; Okada, Y.; Saito, K.; Tanikawa, R.; Sawamukai, N.; Sasaguri, Y.; Kohro, T.; Wada, Y.; Kodama, T.; Tanaka, Y. Rheumatoid synovial endothelial cells produce macrophage colony-stimulating factor leading to osteoclastogenesis in rheumatoid arthritis Rheumatology 2007, 46, 597-603 (Pubitemid 46523302)
14. Kawaji, H.; Yokomuro, K.; Kikuchi, K.; Somoto, Y.; Shirai, Y. Macrophage colony-stimulating factor in patients with rheumatoid arthritis Nippon Ika Daigaku Zasshi 1995, 62, 260-270
15. Ritchlin, C.; Dwyer, E.; Bucala, R.; Winchester, R. Sustained and distinctive patterns of gene activation in synovial fibroblasts and whole synovial tissue obtained from inflammatory synovitis Scand. J. Immunol. 1994, 40, 292-298 (Pubitemid 24272136)
16. Takei, I.; Takagi, M.; Ida, H.; Ogino, T.; Santavirta, S.; Konttinen, Y. T. High macrophage-colony stimulating factor levels in synovial fluid of loose artificial hip joints J. Rheumatol. 2000, 27, 894-899 (Pubitemid 30389743)
17. Bischof, R. J.; Zafiropoulis, D.; Hamilton, J. A.; Campbell, I. K. Exacerbation of acute inflammatory arthritis by the colony-stimulating factors CSF-1 and granulocyte macrophage (GM-CSF): Evidence of macrophage infiltration and local proliferation Clin. Exp. Immunol. 2000, 119, 361-367 (Pubitemid 30073043)
18. Abd, A. H.; Savage, N. W.; Halliday, W. J.; Hume, D. A. The role of macrophages in experimental arthritis induced by Streptococcus agalactiae sonicate: actions of macrophage colony-stimulating factor (CSF-1) and other macrophage-modulating agents Lymphokine Cytokine Res. 1991, 10, 43-50
19. Campbell, I. K.; Rich, M. J.; Bischof, R. J.; Hamilton, J. A. The colony-stimulating factors and collagen-induced arthritis: Exacerbation of disease by M-CSF and G-CSF and requirement for endogenous M-CSF J. Leukocyte Biol. 2000, 68, 144-150
20. Ohno, H.; Uemura, Y.; Murooka, H.; Takanashi, H.; Tokieda, T.; Ohseki, Y.; Kubo, K.; Serizawa, I. The orally-active and selective c-Fms tyrosine kinase inhibitor Ki20227 inhibits disease progression in a collagen-induced arthritis mouse model Eur. J. Immunol. 2008, 38, 283-298
21. Huang, H.; Hutta, D. A.; Rinker, J. M.; Hu, H.; Parsons, W. H.; Schubert, C.; DesJarlais, R. L.; Crysler, C. S.; Chaikin, M. A.; Donatelli, R. R.; Chen, Y.; Cheng, D.; Zhou, Z.; Yurkow, E.; Manthey, C. L.; Player, M. R. Pyrido[2,3- d ]pyrimidin-5-ones: A novel class of antiinflammatory macrophage colony-stimulating factor-1 receptor inhibitors J. Med. Chem. 2009, 52, 1081-1091
22. Meyers, M. J.; Pelc, M.; Kamtekar, S.; Day, J.; Poda, G. I.; Hall, M. K.; Michener, M. L.; Reitz, B. A.; Mathis, K. J.; Pierce, B. S.; Parikh, M. D.; Mischke, D. A.; Long, Sa. A.; Parlow, J. J.; Anderson, D. A.; Thorarensen, A. Structure-based drug design enables conversion of a DFG-in binding CSF-1R kinase inhibitor to a DFG-out binding mode Bioorg. Med. Chem. Lett. 2010, 20, 1543-1547
23. Paniagua, R. T.; Chang, A.; Mariano, M. M.; Stein, E. A.; Wang, Q.; Lindstrom, T. M.; Sharpe, O.; Roscow, C.; Ho, P. P.; Lee, D. M.; Robinson, W. H. c-Fms-mediated differentiation and priming of monocyte lineage cells plays a central role in autoimmune arthritis Arthritis Res. Ther. 2010, 12, R32
24. Ando, W.; Hashimoto, J.; Nampei, A.; Tsuboi, H.; Tateishi, K.; Ono, T.; Nakamura, N.; Ochi, T.; Yoshikawa, H. Imatinib mesylate inhibits osteoclastogenesis and joint destruction in rats with collagen-induced arthritis (CIA) J. Bone Miner. Metab. 2006, 24, 274-282 (Pubitemid 43992670)
25. Manthey, C. L.; Johnson, D. L.; Illig, C. R.; Tuman, R. W.; Zhou, Z.; Baker, J. F.; Chaikin, M. A.; Donatelli, R. R.; Franks, C. F.; Zeng, L.; Crysler, C.; Chen, Y.; Yurkow, E. J.; Boczon, L.; Meegalla, S. K.; Wilson, K. J.; Wall, M. J.; Chen, J.; Ballentine, S. K.; Ott, H.; Baumann, C.; Lawrence, D.; Tomczuk, B. E.; Molloy, C. J. JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia Mol. Cancer Ther. 2009, 8, 3151-3161
26. Miyaura, N.; Suzuki, A. Palladium-catalyzed cross-coupling reactions of organoboron compounds Chem. Rev. 1995, 95, 2457-2483
27. Wustrow, D. J.; Wise, L. D. Coupling of arylboronic acid with a partially reduced pyridine derivative Synthesis 1991, 993-995
28. Wall, M. J.; Schubert, C.; Illig, C. R. Cyano-substituted 2-carboxyimidazoles: Synthesis of 4-cyano-1-{[2-(trimethylsilyl)ethoxy]methyl}- 1H-imidazole-2-carboxylate potassium salt Synthesis 2008, 3377-3379
29. Wall, M. J.; Chen, J.; Meegalla, S.; Ballentine, S. K.; Wilson, K. J.; DesJarlais, R. L.; Schubert, C.; Chaikin, M. A.; Crysler, C. S.; Petrounia, I.; Donatelli, R. R.; Yurkow, E. J.; Boczon, L.; Mazzula, M.; Player, M. R.; Patch, R. J.; Manthey, C. L.; Molloy, C. J.; Tomczuk, B. E.; Illig, C. R. Synthesis and evaluation of novel 3,4,6-substituted 2-quinolones as FMS kinase inhibitors Bioorg. Med. Chem. Lett. 2008, 18, 2097
30. Patch, R. J.; Brandt, B. M.; Asgari, D.; Baindur, N.; Chadra, N. K.; Georgiadas, T.; Cheung, W. S.; Petrounia, I.; Donatelli, R. R.; Chaikin, M. A.; Player, M. R. Potent 2-aminoanilide inhibitors of cFMS as potential anti-inflammatory agents Bioorg. Med. Chem. Lett. 2007, 17, 6070
31. Schubert, C.; Schalk-Hihi, C.; Struble, G. T.; Ma, H. C.; Petrounia, I. P.; Brandt, B.; Deckman, I. C.; Patch, R. J.; Player, M. R.; Spurlino, J. C.; Springer, B. A. Crystal structure of the tyrosine kinase domain of colony-stimulating factor-1 receptor (cFMS) in complex with two inhibitors J. Biol. Chem. 2007, 282, 4094-4101 PDB ID: 2I0Y (Pubitemid 47084443)
32. Illig, C. R.; Chen, J.; Wall, M. J.; Wilson, K. J.; Ballentine, S. K.; Rudolph, M. J; DesJarlais, R. L.; Chen, Y.; Schubert, C.; Petrounia, I.; Crysler, C. S.; Molloy, C. J.; Chaikin, M. A.; Manthey, C. L.; Player, M. R.; Tomczuk, B. E.; Meegalla, S. K. Discovery of novel FMS kinase inhibitors as anti-inflammatory agents Bioorg. Med. Chem. Lett. 2008, 18, 1642-1648 (Pubitemid 351343803)
33. Kaplowitz, N. Idiosyncratic drug hepatotoxicity Nature Rev. Drug Discovery 2005, 4, 489-499 (Pubitemid 40861991)
34. Ju, C.; Uetrecht, J. P. Mechanism of idiosyncratic drug reactions: Reactive metabolite formation, protein binding and the regulation of the immune system Curr. Drug Metab. 2002, 3, 367-377 (Pubitemid 34778003)
35. Singh, R.; Silva Elipe., M. V.; Pearson, P. G.; Arison, B. H.; Wong, B. K.; White, R.; Yu, X.; Burgey, C. S.; Lin, J. H.; Baillie, T. A. Metabolic activation of a pyrazinone-containing thrombin inhibitor. Evidence for novel biotransformation involving pyrazinone ring oxidation, rearrangement, and covalent binding to proteins Chem. Res. Toxicol. 2003, 16, 198-207 (Pubitemid 36245869)
36. Meegalla, S. K.; Wall, M. J.; Chen, J.; Wilson, K. J.; Ballentine, S. K.; DesJarlais, R. L.; Schubert, C.; Crysler, C. S.; Chen, Y.; Molloy, C. J.; Chaikin, M. A.; Manthey, C. L.; Player, M. R.; Tomczuk, B. E.; Illig, C. R. Structure-based optimization of a potent class of arylamide FMS inhibitors Bioorg. Med. Chem. Lett. 2008, 18, 3632-3637 (Pubitemid 351795594)
37. Illig, C. R.; Ballentine, S. K.; Chen, J.; Meegalla, S.; Rudolph, J.; Wall, M. J.; Wilson, K. J.; Desjarlais, R.; Manthey, C. L.; Flores, C. M.; Molloy, C. J. Preparation of aromatic amides as inhibitors of c-fms kinase. PCT Int. Pat. Appl. WO 2006047504 A1, 2006.
38. RCSB Protein Data Bank. An Information Portal to Biological MacromolecularStructures. http://www.rcsb.org/pdb/explore/explore.dostructureId= 3KRL (accessed December 30, 2010).
39. RCSB Protein Data Bank. An Information Portal to Biological Macromolecular Structures. http://www.rcsb.org/pdb/explore/explore. dostructureId=3KRJ (accessed December 30, 2010).
40. DeLano, W. L. The PyMOL Molecular Graphics System; DeLano Scientific: Palo Alto, CA, 2002; http://www.pymol.org (accessed November 17, 2010).
41. Orlofsky, A.; Stanley, E. R. CSF-1-induced gene expression in macrophages; dissociation from the mitogenic response EMBO J. 1987, 6, 2947-2952
42. The Cerep high-throughput profile consists of a broad collection of 50 transmembrane and soluble receptors, ion channels, and monoamine transporters designed to provide information not only on potential limitations or liabilities of drug candidates but also for off-target activity identification. For the test compounds, the results are expressed as a percent inhibition of control-specific binding (mean values, n = 2); http://www.cerep.fr/Cerep/Users/ index.asp (accessed December 30, 2010).
43. a of the conjugate acid of the piperidine was calculated using Advanced Chemistry Development (ACD/Labs) Software v12.0; http://www.acdlabs.com (accessed September 10, 2010).
44. Peters, J.-U.; Schnider, P.; Mattei, P.; Kansy, M. Pharmacological promiscuity: Dependence on compound properties and target specificity in a set of recent Roche compounds ChemMedChem 2009, 4, 680-686
45. Azzaoui, K.; Hamon, J.; Faller, B.; Whitebread, S.; Jacoby, E.; Bender, A.; Jenkins, J. J.; Urban, L. Modeling promiscuity based on in vitro safety pharmacology profiling data ChemMedChem 2007, 2, 874-880
46. Leeson, P. D.; Springthorpe, B. The influence of drug-like concepts on decision-making in medicinal chemistry Nature Rev. Drug Discovery 2007, 6, 881-890 (Pubitemid 350042396)
47. Macchiarulo, A.; Nuti, R.; Eren, G.; Pellicciari, R. Charting the chemical space of target sites: Insights into the binding modes of amine and amidine groups J. Chem. Inf. Model. 2009, 49, 900-912
48. Starmer, C. F.; Lancaster, A. R.; Lastra, A. A.; Grant, A. O. Cardiac instability amplified by use-dependent sodium channel blockade Am. J. Physiol. 1992, 262, H1305-H1310
49. Hiroaka, M. In Electrical Diseases of the Heart: Genetics, Mechanisms, Treatment, Prevention; Gussak, I.; Antzelevitch, C.; Wilde, A. A. M.; Friedman, P. A.; Ackerman, M. J.; Shen, W.-K., Eds.; Springer: London, 2008; pp 691-704.
50. Clusin, W. T. Calcium and cardiac arrhythmias: DADs, EADs, and alternans Crit. Rev. Clin. Lab. Sci. 2003, 40, 337-375 (Pubitemid 36774245)
51. Salhanick, S. D.; Shannon, M. W. Management of calcium channel antagonist overdose Drug Saf. 2003, 26, 65-79 (Pubitemid 36188558)
52. Packer, M. Pathophysiological mechanisms underlying the adverse effects of calcium channel-blocking drugs in patients with chronic heart failure Circulation 1989, 80, IV59-IV67
53. Wilson, K. J.; Illig, C. R.; Chen, J.; Wall, M. J.; Ballentine, S. K.; DesJarlais, R. L.; Chen, Y.; Schubert, C.; Donatelli, R.; Petrounia, I.; Crysler, C. S.; Molloy, C. J.; Chaikin, M. A.; Manthey, C. L.; Player, M. R.; Tomczuk, B. E.; Meegalla, S. K. Reducing ion channel activity in a series of 4-heterocyclic arylamide FMS inhibitors Bioorg. Med. Chem. Lett. 2010, 20, 3925-3929
54. 4 receptor with improved selectivity over ion channels Bioorg. Med. Chem. 1998, 6, 743-753 (Pubitemid 28287276)
55. Ladduwahetty, T.; Boase, A. L; Mitchinson, A.; Quin, C.; Patel, S.; Chapman, K.; MacLeod, A. M. A new class of selective, non-basic 5-HT2A receptor antagonists Bioorg. Med. Chem. Lett. 2006, 16, 3201-3204
56. Jamieson, C.; Moir, E. M.; Rancovic, Z.; Wishart, G. Medicinal chemistry of hERG optimizations: Highlights and hang-ups J. Med. Chem. 2006, 49, 5029-5046 (Pubitemid 44260200)
57. Bertz, R. J.; Granneman, G. R. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions Clin. Pharmacokinet. 1997, 32, 210-258 (Pubitemid 27122521)
58. Masimirembwa, C. M.; Thompson, R.; Andersson, T. B. In vitro high throughput screening of compounds for favorable metabolic properties in drug discovery Comb. Chem. High Throughput Screening 2001, 4, 245-263 (Pubitemid 32433637)
59. Morgenthaler, M.; Schwiezer, E.; Hoffmann-Roder, A.; Benini, F.; Martin, R. E.; Jaeschke, G.; Wagner, B.; Fischer, H.; Bendels, S.; Zimmerli, D.; Schneider, J.; Diederich, F.; Kansy, M.; Muller, K. Predicting and tuning physicochemical properties in lead optimization: Amine basicities ChemMedChem 2007, 2, 1100-1115
60. Sanguinetti, M. C.; Tristani-Firouzi, M. hERG potassium channels and cardiac arrhythmia Nature 2006, 440, 463-469
61. Sanguinetti, M. C.; Mitcheson, J. S. Predicting drug-hERG channel interactions that cause acquired long QT syndrome Trends Pharmacol. Sci. 2005, 26, 119-124 (Pubitemid 40313590)
62. Geissler, E. N.; Ryan, M. A.; Housman, D. E. The dominant-white spotting (W) locus of the mouse encodes the c-kit proto-oncogene Cell 1988, 55, 185-192
63. Bijangi-Vishehsaraei, K.; Saadatzadeh, M. R.; Werne, A.; Wilson McKenzie, K. A.; Kapur, R.; Ichijo, H.; Haneline, L. S. Enhanced TNF-alpha-induced apoptosis in Fanconi anemia type C-deficient cells is dependent on apoptosis signal-regulating kinase 1 Blood 2005, 106, 4124-4130 (Pubitemid 41775917)
64. Trentham, D. E.; Townes, A. S.; Kang, A. H. Autoimmunity to type II collagen: an experimental model of arthritis J. Exp. Med. 1977, 146, 857-868 (Pubitemid 8175993)
65. Bendele, A. M. Animal models of rheumatoid arthritis J. Musculoskeletal Interact. 2001, 1, 377-385
66. Joosten, L. A. B.; Helsen, M. M. A.; Van de Loo, F. A. J.; Van den Berg, W. B. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: A comparative study using anti-TNF, anti-IL-1/, and IL-1Ra Arthritis Rheum. 1996, 39, 797-809
67. De Clerck, F.; Van de Water, A.; D'Aubioul, J.; Lu, H. R.; van Rossem, K.; Hermans, A.; Van Ammel, K. In vivo measurement of QT prolongation, dispersion and arrythmogenesis: Application to the preclinical cardiovascular safety pharmacology of a new chemical entity Fundam. Clin. Pharmacol. 2002, 16, 125-140 (Pubitemid 34587797)
68. Ueno, Y.; Okazaki, S.; Isogaya, M.; Nishio, S.; Tanaka, H.; Kato, Y.; Shigenobu, K. Positive inotropic and chronotropic effects of beraprost sodium, a stable analog of prostacyclin, in isolated guinea pig myocardium Gen. Pharmacol. 1996, 27, 101-103
69. Pearson, C. M. Development of arthritis, periarthritis and periostitis in rats given adjuvants Proc. Soc. Exp. Biol. Med. 1956, 91, 95-100
70. Carlson, R. P.; Datko, L. J.; O'Neil-Davis, L.; Blazek, E. M.; Delustro, F.; Beideman, R.; Lewis, A. J. Comparison of inflammatory changes in established type II collagen and adjuvant induced arthritis using outbred Wistar rats Int. J. Immunopharmacol. 1985, 7, 811-826 (Pubitemid 16213248)
71. Benslay, D. N.; Bendele, A. M. Development of a rapid screen for detecting and differentiating immunomodulatory vs. anti-inflammatory compounds in rats Agents Actions 1991, 34, 254-256
72. Chang, Y. Adjuvant polyarthritis Arthritis Rheum. 1980, 23, 62-71
73. Cromartie, W. J.; Craddock, J. G.; Schwab, J. H.; Anderlie, S. K.; Yang, C. Arthritis in rats after systemic injection of streptococcal cells or cell walls J. Exp. Med. 1977, 146, 1585-1602 (Pubitemid 8245443)
74. Richards, P. J.; Williams, B. D.; Williams, A. S. Suppression of chronic streptococcal cell wall-induced arthritis in lewis rats by liposomal clodronate Rheumatology 2001, 40, 978-987
75. Wustrow, D. J.; Wise, L. D. Coupling of arylboronic acids with a partially reduced pyridine derivative Synthesis 1991, 993-995
76. Maier, J. A.; Brugel, T. A.; Sabat, M.; Golebiowski, A.; Laufersweiler, M. J.; VanRens, J. C.; Hopkins, C. R.; De, B.; Hsieh, L. C.; Brown, K. K.; Easwaran, V.; Janusz, M. J. Development of N -4,6-pyrimidine- N -alkyl- N -phenyl ureas as orally active inhibitors of lymphocyte specific tyrosine kinase Bioorg. Med. Chem. Lett. 2006, 16, 3646-3650 (Pubitemid 44164265)